Psilera Begins Phase 2 Research on Alcohol Use Disorder Treatment

TAMPA, Fla., Oct. 8, 2026 /CourierPR/ -- Psilera Inc., a leading biopharmaceutical company pioneering next-generation neuroplastogens and psychedelic therapies, has announced the initiation of Phase 2 of its SBIR NIH-backed research into Alcohol Use Disorder (AUD). The company's Phase 2 research will further investigate the potential of non-hallucinogenic psilocybin derivatives to treat addiction disorders, with the support of the National Institutes of Health (NIH).

Phase 1 of Psilera's grant work with the National Institutes of Alcohol Abuse and Alcoholism (NIAAA) began in October of last year. Psilera delivered timely, promising results, further advancing its preclinical work ahead of its anticipated Phase 1a clinical trial in 2027. The Phase 1a clinical trial will be a significant step towards testing the efficacy of Psilera's lead product candidate, PSIL-006, a first-in-class therapy designed to rapidly deliver the neuroplastic benefits of traditional psychedelics without the limitations of traditional side effects.

Alcohol Use Disorder (AUD) is a serious and debilitating condition characterized by an impaired ability to stop or control alcohol use despite adverse social, occupational, or health consequences. AUD encompasses conditions often referred to as alcohol abuse, alcohol dependence, or the colloquial term alcoholism. AUD can cause lasting changes in the brain that make patients vulnerable to relapse in the future.

Psilera's research into non-hallucinogenic psilocybin derivatives represents a promising new approach to treating AUD. The company's Phase 2 research will build upon these promising preclinical results, with the goal of advancing the development of a potential new treatment for AUD. This research underscores the continued momentum behind the development of next-generation psychedelics and neuroplastogens for addictive disorders.

The National Institutes of Health (NIH) is a federal agency of the United States Department of Health and Human Services that conducts and supports medical research. The National Institute on Alcohol Abuse and Alcoholism (NIAAA) is one of the NIH institutes that conducts and supports research on the causes, prevention, and treatment of alcohol use disorders, as well as the consequences of alcohol abuse and alcoholism.

Psilera is a leading biopharmaceutical company, engineering tomorrow's therapies by leveraging the therapeutic potential of neuroplastogens. Leading the charge in its robust, wholly owned pipeline of novel therapeutics is PSIL-006, a first-in-class therapy designed to rapidly deliver the neuroplastic benefits of traditional psychedelics without the limitations of traditional side effects. Driven by relentless scientific excellence and a passion for transforming the patient experience, Psilera is engineering a new era of mindful medicine.